Activist Investor Cevian Capital Raises Stake in Smith & Nephew to 14.2%
The Jersey-based investment firm increased its position through two investment vehicles, now holding 119.2 million voting rights in the British medical device maker.
Cevian Increases Smith & Nephew Holdings
Cevian Capital II GP Limited has increased its stake in Smith & Nephew plc to 14.214414% of voting rights, up from a previously notified position of 14.010786%, according to a TR-1 regulatory filing disclosed on August 12, 2026. The Jersey-based investment firm crossed the threshold on August 7, 2026 (6-K filing, 2026-08-12).
The increased position represents 119,179,419 voting rights in the UK-based medical device manufacturer, which currently trades at approximately $11.08 with a market capitalization of around $13 billion.
Breakdown of Investment Vehicles
Cevian's holdings are distributed across two investment vehicles. The Cevian Capital II Master Fund L.P. now holds 13.014856% of voting rights, up from a previously notified 12.815710%. The Cevian Capital II Co-Investment - Series P L.P. holds 1.199558%, compared to the previous notification of 1.195075% (6-K filing, 2026-08-12).
According to the filing, Cevian Capital II G.P. Limited acts as general partner for both investment vehicles. The shares are legally owned by Aurora Nominees Limited, acting as nominee and holding the shares on behalf of UBS AG, which serves as custodian (6-K filing, 2026-08-12).
No New Notification Threshold Crossed
Despite the increase in holdings, the filing noted that "Cevian Capital II G.P. Limited has not crossed a new notification threshold as a result of this increase" (6-K filing, 2026-08-12). The notification was made for transparency purposes following the firm's previous disclosure dated July 24, 2026.
The TR-1 form is a standard UK regulatory requirement for notification of major holdings, triggered by acquisitions or disposals of voting rights or events changing the breakdown of voting rights.
Cevian's Activist Profile
Cevian Capital is known as one of Europe's most prominent activist investors, typically taking significant stakes in companies where it believes operational improvements or strategic changes can unlock shareholder value. The firm's increased position in Smith & Nephew signals continued confidence in the medical technology company, which specializes in orthopedic reconstruction, sports medicine, and advanced wound management.
Recent Corporate Activity
According to MarginX data, Smith & Nephew has seen recent insider activity, with transactions including sales by executives Craig Gaffin (1,401 shares) and Elga Lohler (13,120 shares). The company is scheduled to pay a cash dividend of $0.156 on October 1, 2026, and is expected to report third-quarter 2026 results on November 5, 2026.
The filing was signed by Helen Barraclough, Company Secretary, on August 12, 2026, pursuant to the requirements of the Securities Exchange Act of 1934 (6-K filing, 2026-08-12).
This article was generated by MarginX from the 6-K filing on 2026-08-12. It is not investment advice.